trametinib – Medxy AI

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial

By MedXY 08/13/2026

The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression-free survival endpoint.

news Oncology

Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy

By Zhang Paul 01/12/2026

Highlights High tumour pERK expression (histoscore >140) is a significant predictor of prolonged progression-free survival…

Clinical Updates news Oncology

Targeting the MEK/RTK Axis: A Promising Combination Therapy for KRAS-Mutant Non-Small Cell Lung Cancer

By MedXY 09/19/2025

Combining MEK inhibitor trametinib with pan-RTK inhibitor anlotinib shows high efficacy and manageable toxicity in treating advanced non-G12C KRAS-mutant NSCLC, overcoming adaptive resistance and offering improved clinical outcomes.